[go: up one dir, main page]

WO2012036589A1 - Composition à base d'hydrogel pour le traitement de brûlures - Google Patents

Composition à base d'hydrogel pour le traitement de brûlures Download PDF

Info

Publication number
WO2012036589A1
WO2012036589A1 PCT/RU2011/000617 RU2011000617W WO2012036589A1 WO 2012036589 A1 WO2012036589 A1 WO 2012036589A1 RU 2011000617 W RU2011000617 W RU 2011000617W WO 2012036589 A1 WO2012036589 A1 WO 2012036589A1
Authority
WO
WIPO (PCT)
Prior art keywords
mass
burns
treatment
composition
hydrogel composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2011/000617
Other languages
English (en)
Russian (ru)
Inventor
Валерий Владимирович БОЯРИНЦЕВ
Виктор Борисович НАЗАРОВ
Александр Сергеевич САМОЙЛОВ
Алексей Вячеславович ДРУЖКОВ
Эдуард Валентинович ФРОНЧЕК
Антон Юрьевич БЕЛОВОЛОВ
Ольга Юрьевна САВВАТЕЕВА
Наталья Владимировна СЕРЕДА
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FEDERALNOE GOSUDARSTVENNOE UNITARNOE PREDPRIYATIE "FARMZASCHITA"
Original Assignee
FEDERALNOE GOSUDARSTVENNOE UNITARNOE PREDPRIYATIE "FARMZASCHITA"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FEDERALNOE GOSUDARSTVENNOE UNITARNOE PREDPRIYATIE "FARMZASCHITA" filed Critical FEDERALNOE GOSUDARSTVENNOE UNITARNOE PREDPRIYATIE "FARMZASCHITA"
Publication of WO2012036589A1 publication Critical patent/WO2012036589A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • the invention relates to medicine, in particular to pharmacology, namely, to the means used for first aid for burns in emergency medicine, can be used for topical treatment of wounds at all stages of complex treatment, in patients with radiation, thermal and sunburn I -IIIA, as well as the treatment of granular wounds of various etiologies, for the treatment of insect bite sites.
  • a known composition for treating burns is the Likozol aerosol, developed on the basis of the well-known domestic drug Lyoxazole, produced in the form of an aerosol, which has many years of use for the prevention and treatment of acute local radiation injuries of the skin of I and II severity (patent RU 2058777 " Aerosol preparation for the treatment of radiation burns ", IPC A61K9 / 12, 1996.).
  • This technical solution is the closest to the claimed invention, therefore, it is taken as a prototype.
  • the disadvantage of the prototype is the limited use for the treatment of deep burns due to the presence in its composition of alcohol, leading to a sharp burning sensation and soreness.
  • Another disadvantage of the known composition is the use of the drug in the form of a foam aerosol composition of medicinal and biological active compounds, the active principle of which is water-salt 2-AOE, lidocaine (trimecain), collagen and vitamin E.
  • the main therapeutic effect of this complex drug is due to the action of 2-AOE, which has the ability to prevent spasms (sharp narrowing) of the arteries of the skin, improve blood circulation to the skin and accelerate reparative (recovery) processes in the epithelium.
  • hydrogel wound dressings “APPOLO-PAK-AM”, “APPOLO-PAK-AI”, etc., based on a copolymer of acrylamide and acrylic acid with the inclusion of antiseptics miramistin or iodovidone and a local anesthetic anilokain and having a sorption capacity of 2-3 g / g
  • Such coatings have antimicrobial, anti-inflammatory and analgesic effects, but do not contain antienzyme and antioxidant agents, which reduces their effectiveness in purulent-destructive processes.
  • the disadvantage of this drug is the lack of effect on the treatment of radiation burns, which significantly narrows the therapeutic spectrum of the use of this drug in emergency
  • hydrogels their lack of versatility and effectiveness in emergency medicine.
  • the technical result as a result of using the invention is to expand the operational capabilities for first aid for local burns of various etiologies, including radiation at all stages of medical care, as well as for emergency medicine as a universal tool in the treatment of granulating wounds of various etiologies: sluggish; to relieve inflammation in skin diseases, as well as to treat insect bite sites.
  • the hydrogel composition for treating burns contains the active ingredient, auxiliary ingredients and a gelling component.
  • an active ingredient contains a medicinal substance of 2-allyloxyethanol in an amount of from 0.1 to 10.0 (mass,%).
  • auxiliary ingredients it contains medicinal substances of lidocaine or anilocaine in an amount of from 0.1 to 5.0 (mass,%).
  • auxiliary ingredients it contains medicinal substances of lidocaine or anilocaine in an amount of from 0.1 to 5.0 (mass,%) and deoxinate in an amount of from 0.1 to 5.0 (mass,%).
  • a gelling component contains hydroxypropyl cellulose in an amount of from 0.1 to 5.0 (mass,%).
  • the active ingredient consists of immobilized 2-allyloxyethanol in a concentration of (4.0 ⁇ 0.5)%.
  • the auxiliary ingredient includes immobilized lidocaine in a concentration of (2.5 ⁇ 0.5)%.
  • the auxiliary ingredient includes immobilized anilocaine in a concentration of (2.5 ⁇ 0.5)%.
  • the auxiliary ingredient includes immobilized deoxinate at a concentration of (0.3 ⁇ 0.1)%.
  • Hydrogel composition additionally contains at least one of the substrates: fabric or non-woven material, mesh fabric in their mass ratio to the gel-forming component as 1: 3 ... 1: 8.
  • the dressing is hydrogel, anti-burn, sterile "LIOXAZINE D-Gel” based on hydroxypropyl cellulose with immobilized 2 - allyloxyethanol, deoxyribonucleate (deoxinate) and lidocaine in an individual package.
  • hydrogel anti-burn agents have a local anesthetic, anti-inflammatory and regenerative stimulating effect on burns of various etiologies, including radiation.
  • the proposed anti-burn agents are highly effective. They have a pronounced wound healing effect in the 1st, 2nd and 3rd phases of the wound process and affect reparative processes in the epithelium, improving microcirculation of the dermal vessels by preventing early spasm of the arteries of the deep vascular plexus of the skin; participate in the weakening of pathological afferentation from affected areas that occurs when exposed to ionizing radiation on the skin, burns of any etiology; activate the growth of granulations and epithelium.
  • Antimicrobial activity is associated with stunted microflora under St.epid specimens. and Ps. aeroginosa.
  • the therapeutic effect of drugs it is provided by the combined effect of incoming components, affecting several pathological links, namely: pain, drying or swelling of the wound and infection of the burn surface.
  • Anti-burn hydrogels which are a composition of medicinal compounds consisting of 2-AOE and lidocaine (sodium deoxyribonucleate (deoxinate) added by LIOXAZIN D-Gel) provides a complex multifactorial effect on the course of a complicated wound process.
  • Lidocaine in combination with a cooling effect provides rapid anesthesia of damaged tissues.
  • 2-AOE prevents the disorder of the microvasculature, promotes the activation of proliferation in tissues that have remained viable, improves blood circulation in the affected area and accelerates the reparative processes in the epithelium.
  • Sodium deoxyribonucleate (deoxynate) - is a narrow fraction of the sodium salt of deoxyribonucleic acid.
  • Sodium deoxyribonucleate has immunomodulating, anti-inflammatory, reparative, regenerating actions. It activates antiviral, antifungal and antimicrobial immunity at the cellular and humoral levels. Regulates hematopoiesis, normalizing the number of leukocytes, granulocytes, phagocytes, lymphocytes and platelets. Corrects the state of tissues and organs with dystrophy of vascular origin, exhibits weak anticoagulant properties. Accelerates the rejection of necrotic masses. Stimulates the reparative processes of damaged areas of the skin and mucous membranes. Facilitates engraftment of autografts during skin grafts.
  • the claimed product has no contraindications, it is harmless, does not cause allergic reactions, has no age restrictions, does not require additional use of other drugs, including antibacterial drugs, etc.
  • the wounds were cleaned of foreign bodies, blood clots to ensure maximum contact of the drug with the surface of the wound.
  • Dressing, hydrogel, anti-burn sterile dressings were used in 15 patients (RAS hospital): in 10 patients in the treatment of granulating long-wound wounds; in 5 patients in the treatment of thermal burns.
  • Example 1 Patient N, 53 years old, as a result of a domestic fire received a burn (flame) of both upper limbs of I-II degree, the burn surface area was 5%. Upon examination, the condition is satisfactory. For organs without features. Locally: hyperemia, moderate swelling of the skin, in some places the epidermis detachment with the formation of blisters. For the purpose of local conservative treatment of burn wounds, the anti-burn hydrogel "Lyoxazine-SP" was used, a positive effect was noted already with a single use of the drug. Complete healing of wounds was noted by 7 days, without scarring.
  • Example 2 Patient K, 62 years old, received a burn with boiling water of the right lower leg and outer surface of the foot of the II-IIIA degree. The wound surface area was 3%. Within 10 days of the use of symptomatic therapy, dressings with solutions of antiseptics, drying of burn wounds, positive dynamics were noted, however, the growth of granulations was slowed down. Locally: de-epithelized wound surface, moist, pale pink with a touch of fibrin, without mucopurulent discharge, sensitivity preserved, moderate swelling of surrounding tissues. Local conservative treatment of burn wounds using napkins with anti-burn hydrogel "Lyoxazine-D-Gel". On the 17th day after the injury, complete epithelization of burn wounds was noted. At Hospital N ° 122, hydrogel dressings were used in conservative therapy in 12 patients, 3 of them showed long-term skin wounds, and 9 patients used to treat burns.
  • Example 3 Patient P, 39 years old, received a burn with boiling oil of the left forearm and hand II-IIIA degree, with an area of damage of 2%. The patient was admitted 2 days after the injury. The burn wound was characterized by de-epithelial areas, with moderately purulent discharge, swelling of the surrounding skin was noted. Antibacterial, symptomatic therapy was prescribed, the anti-burn hydrogel “Lyoxazine-Gel” was used as a local treatment for the burn wound, epithelialization sites were noted on days 10-11, and on day 19 the burn wound was completely epithelized.
  • the use of the product helps to reduce exudation from wound surfaces, accelerates the appearance of granulations and zones of epithelization, reduces the healing time;
  • the use of the claimed means allows the use of anti-burn hydrogels in first aid for local burns of various etiologies, including radiation at all stages of medical care, as well as the treatment of places of insect bites. With the possibility of use in emergency medicine as a universal anti-burn agent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne le domaine de la médecine et notamment de la pharmacologie, et concerne notamment des moyens utilisés pour les premiers secours en cas de brûlure dans des interventions médicales d'urgence; elle peut s'utiliser pour le traitement local de blessures à tous les stades d'un traitement intégré chez les malades souffrant de brûlures radiologiques, thermiques ou solaires I-III A, ainsi que pour le traitement de blessures granuleuses d'étiologie variable et à des fins de traitement de piqures d'insectes. Le résultat technique de l'utilisation de l'invention est un plus large éventail de possibilités de premiers secours en cas de brûlures locales d'étiologie variable, y compris d'origine radiologique, à tous les stades de secours. La composition à base d'hydrogel pour le traitement de brûlures comprend un ingrédient actif, des ingrédients additionnels et un gélifiant. On utilise en tant qu'ingrédient actif une substance active de 2-allyloxyéthanol dans des quantités entre 0,1 et 10,0 (en % en masse). En tant que composants additionnels on utilise des substances médicamenteuses lidocaïne ou anylocaïne dans des quantités entre 0,1 et 5,0 (en % en masse) et désoxynate dans des quantités entre 0,1 et 5,0 (en % en masse). On utilise en tant que gélifiant l'hydroxypropyl-cellulose dans des quantités entre 0,1 et 5,0 (en % en masse). On utilise des ingrédients actifs ou additionnels immobilisés. La composition à base d'hydrogel comprend en outre un des substrats tels qu'un tissu ou un non-tissé, une toile tramée présentant un rapport de masses avec le gélifiant de 1 :3... 1 :8.
PCT/RU2011/000617 2010-09-16 2011-08-15 Composition à base d'hydrogel pour le traitement de brûlures Ceased WO2012036589A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010138263/15A RU2438654C1 (ru) 2010-09-16 2010-09-16 Гидрогелевая композиция для лечения ожогов
RU2010138263 2010-09-16

Publications (1)

Publication Number Publication Date
WO2012036589A1 true WO2012036589A1 (fr) 2012-03-22

Family

ID=45783845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2011/000617 Ceased WO2012036589A1 (fr) 2010-09-16 2011-08-15 Composition à base d'hydrogel pour le traitement de brûlures

Country Status (2)

Country Link
RU (1) RU2438654C1 (fr)
WO (1) WO2012036589A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2526183C1 (ru) * 2013-02-28 2014-08-20 Федеральное государственное унитарное предприятие Научно-производственный центр "Фармзащита" Федерального медико-биологического агентства (ФГУП НПЦ "Фармзащита" ФМБА России) Гемостатическая противоожоговая ранозаживляющая композиция

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2545729C1 (ru) * 2013-10-15 2015-04-10 Кирилл Николаевич Касанов Сетчатое биоактивное раневое покрытие
RU2545735C1 (ru) * 2013-11-06 2015-04-10 Кирилл Николаевич Касанов Биоактивное гидрогелевое раневое покрытие
RU2545798C1 (ru) * 2014-03-24 2015-04-10 Закрытое акционерное общество "ФИРН М" (ЗАО "ФИРН М") Фармацевтическая композиция для оказания первой медицинской помощи при ожогах различной этиологии, площади и глубины в форме спрея, геля, аэрозоля
RU2564905C1 (ru) * 2014-05-29 2015-10-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Казанская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ лечения больных ограниченной склеродермией
RU2627669C1 (ru) * 2016-07-20 2017-08-09 федеральное государственное бюджетное научное учреждение "Федеральный центр токсикологической, радиационной и биологической безопасности" (ФГБНУ "ФЦТРБ-ВНИВИ") Способ получения продуктов метаболизма бифидобактерий для лечения комбинированного радиационно-термического поражения организма и способ лечения комбинированного радиационно-термического поражения организма
RU2703307C1 (ru) * 2018-09-06 2019-10-16 Сорокин Сергей Михайлович Гидрогелевая композиция для лечения ожогов
RU2691403C1 (ru) * 2018-09-06 2019-06-13 Сорокин Сергей Михайлович Противоожоговое медицинское изделие для лечения ожогов с терапевтическим эффектом
RU2733512C2 (ru) * 2019-03-01 2020-10-02 Общество с ограниченной ответственностью "ПРОФИТ ФАРМ" Средство для лечения обширных поверхностных повреждений кожи, в том числе всех видов ожогов
RU2749369C2 (ru) * 2019-04-30 2021-06-09 Общество с ограниченной ответственностью "ПРОФИТ ФАРМ" Способ лечения обширных поверхностных повреждений кожи

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2058777C1 (ru) * 1988-11-14 1996-04-27 Научно-производственный центр "Фармзащита" Аэрозольный препарат для лечения лучевых ожогов
US6164012A (en) * 1996-08-02 2000-12-26 Bayer Aktiengesellschaft Biological material embedded in hydrogels, a process for the embedding thereof, and its use as artificial seed
GB2403146A (en) * 2003-06-23 2004-12-29 Johnson & Johnson Medical Ltd Wound dressing comprising a hydrogel with an enzyme dispersed therein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2445086C (fr) * 2001-05-01 2008-04-08 A.V. Topchiev Institute Of Petrochemical Synthesis Compositions d'hydrogel
KR100444944B1 (ko) * 2001-05-24 2004-08-18 선바이오(주) 생체 접착제용 폴리에틸렌글리콜 수화젤
US20050191270A1 (en) * 2004-02-27 2005-09-01 Hydromer, Inc. Anti-infectious hydrogel compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2058777C1 (ru) * 1988-11-14 1996-04-27 Научно-производственный центр "Фармзащита" Аэрозольный препарат для лечения лучевых ожогов
US6164012A (en) * 1996-08-02 2000-12-26 Bayer Aktiengesellschaft Biological material embedded in hydrogels, a process for the embedding thereof, and its use as artificial seed
GB2403146A (en) * 2003-06-23 2004-12-29 Johnson & Johnson Medical Ltd Wound dressing comprising a hydrogel with an enzyme dispersed therein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KORYTOVA L.I. ET AL.: "Pprimenenie gidrogelevykh materialov ''Kolegel''TM dlya uluchsheniya kachestva zhizni onkologicheskikh bolnykh s porazheniem orofarengialnoi zony.", PALLIATIVNAYA MEDITSINA I REABILITATSIYA., no. 2, 1 April 2010 (2010-04-01), pages 51 - 55 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2526183C1 (ru) * 2013-02-28 2014-08-20 Федеральное государственное унитарное предприятие Научно-производственный центр "Фармзащита" Федерального медико-биологического агентства (ФГУП НПЦ "Фармзащита" ФМБА России) Гемостатическая противоожоговая ранозаживляющая композиция

Also Published As

Publication number Publication date
RU2438654C1 (ru) 2012-01-10

Similar Documents

Publication Publication Date Title
RU2438654C1 (ru) Гидрогелевая композиция для лечения ожогов
He et al. Development of hydrogel‐based sprayable wound dressings for second‐and third‐degree burns
CN108136026A (zh) 包含阳离子杀生物剂的基于凡士林的组合物
WO2007127390A2 (fr) Matières et procédés pour le traitement de plaies
AU2013316718B2 (en) Improved wound healing compositions comprising microspheres
RU2177314C2 (ru) Состав с антисептическими, репаративными и болеутоляющими свойствами
US20140363486A1 (en) Methods for reducing or altering scar formation
Khorasani et al. The effects of Aloe Vera cream on split-thickness skin graft donor site management: a randomized, blinded, placebo-controlled study
RU2198685C1 (ru) Медицинский полимерный гелевый материал и лечебные средства на его основе
ES2312421T3 (es) Composicion farmaceutica en gel.
RU2119331C1 (ru) Средство для лечения ожоговых ран "витадерм"
RU2526183C1 (ru) Гемостатическая противоожоговая ранозаживляющая композиция
RU2522214C1 (ru) Способ стимуляции заживления ран различного генеза природным антиоксидантом дигидрокверцетином
Furtado et al. Wound healing concepts: contemporary practices and future perspectives
RU2195262C2 (ru) Фармакологическое средство на основе гиалуроновой кислоты, обладающее антимикробным, ранозаживляющим и противовоспалительным действием
RU2188016C1 (ru) Клеевая лечебно-профилактическая композиция
RU2245723C1 (ru) Средство и способ лечения гнойно-воспалительных заболеваний мягких тканей
Swaim et al. Management of small animal distal limb injuries
US20020037319A1 (en) Drug preparations
Mayorova et al. Modern assortment, properties and perspectives of medical dressings improvement of wound treatment
UA121294C2 (uk) Антисептична композиція, яка містить унітіол і диметилсульфоксид, застосування такої композиції та спосіб обробки ран з її використанням
RU2287324C1 (ru) Мазь для лечения ожоговых ран
RU2084221C1 (ru) Антисептическое средство в виде мази
RU2153352C1 (ru) Фармацевтическая композиция, обладающая ранозаживляющим и противовоспалительным действием
RU2852842C1 (ru) Композиция с антисептическим, ранозаживляющим и кровоостанавливающим эффектами для обработки ран в быту и в военно-полевых условиях

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11825513

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11825513

Country of ref document: EP

Kind code of ref document: A1